ASKA Pharmaceutical Holdings Co (TSE:4886) Debt-to-Equity : 0.17 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is ASKA Pharmaceutical Holdings Co Debt-to-Equity?

ASKA Pharmaceutical Holdings Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円3,180 Mil. ASKA Pharmaceutical Holdings Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円6,925 Mil. ASKA Pharmaceutical Holdings Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was 円60,390 Mil. ASKA Pharmaceutical Holdings Co's debt to equity for the quarter that ended in Dec. 2023 was 0.17.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ASKA Pharmaceutical Holdings Co's Debt-to-Equity or its related term are showing as below:

TSE:4886' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.17 Med: 0.25 Max: 0.36
Current: 0.17

During the past 2 years, the highest Debt-to-Equity Ratio of ASKA Pharmaceutical Holdings Co was 0.36. The lowest was 0.17. And the median was 0.25.

TSE:4886's Debt-to-Equity is ranked better than
63.37% of 849 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs TSE:4886: 0.17

ASKA Pharmaceutical Holdings Co Debt-to-Equity Historical Data

The historical data trend for ASKA Pharmaceutical Holdings Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASKA Pharmaceutical Holdings Co Debt-to-Equity Chart

ASKA Pharmaceutical Holdings Co Annual Data

Trend

Mar22

Mar23

Debt-to-Equity

0.29

0.23

ASKA Pharmaceutical Holdings Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial						0.24	0.23	0.19	0.18	0.17

Competitive Comparison of ASKA Pharmaceutical Holdings Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ASKA Pharmaceutical Holdings Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ASKA Pharmaceutical Holdings Co's Debt-to-Equity falls into.

ASKA Pharmaceutical Holdings Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ASKA Pharmaceutical Holdings Co's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3438	+	9185)	/	54531
	=	0.23

ASKA Pharmaceutical Holdings Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3180	+	6925)	/	60390
	=	0.17

ASKA Pharmaceutical Holdings Co (TSE:4886) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ASKA Pharmaceutical Holdings Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ASKA Pharmaceutical Holdings Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ASKA Pharmaceutical Holdings Co (TSE:4886) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ASKA Pharmaceutical Holdings Co Ltd (TSE:4886) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-5-1 Shibaura, Minato-ku, Tokyo, JPN, 108-8532

Website

https://www.aska-pharma-hd.co.jp

ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and related operations.

ASKA Pharmaceutical Holdings Co (TSE:4886) Headlines

No Headlines